The SU2C-LUNGevity-American Lung Association (ALA) Lung Cancer Interception Research Team hypothesizes that the early detection of invasive lung cancers can be improved through new technological approaches, and that progress on this front can quickly bring about more effective patient treatments. The team is working to build a new tool―a composite of blood-based biomarker tests called the Lung Cancer Interception Assay―that can be used in conjunction with standard imaging to provide early detection of lung cancer.